1.10

0.90% -0.01

After Hours: 1.10

Ensysce Biosciences Inc (ENSC)

Overview News Price History Financials Discussions Forecast Stock Split

Ensysce Biosciences Inc stock is traded at $1.10, with a volume of 61,200. It is down -0.90% in the last 24 hours and down -37.85% over the past month. Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Previous Close:

$1.11

Open:

$1.09

24h Volume:

61,200

Relative Volume:

0.29

Market Cap:

$4.00M

Revenue:

Net Income/Loss:

$-11.28M

P/E Ratio:

-0.3654

EPS:

-3.01

Net Cash Flow:

$-9.78M

1W Performance:

-5.17%

1M Performance:

-37.85%

6M Performance:

-50.45%

1Y Performance:

-88.25%

1-Day Range:

$1.08

$1.14

1-Week Range:

$1.08

$1.24

52-Week Range:

$1.08

$9.57

Ensysce Biosciences Inc Stock (ENSC) Company Profile

Name

Ensysce Biosciences Inc

Sector

Healthcare (1131)

Industry

Biotechnology (633)

Phone

(858) 263-4196

Address

7946 IVANHOE AVENUE, LA JOLLA

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ENSC's Discussions on Twitter

Compare ENSC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENSC Ensysce Biosciences Inc	1.10	4.03M	0	-11.28M	-9.78M	-3.01
VRTX Vertex Pharmaceuticals Inc	462.90	117.47B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	784.97	82.37B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.59	52.94B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	844.92	52.33B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.88	37.84B	447.02M	-1.18B	-906.14M	-6.1812

Ensysce Biosciences Inc Stock (ENSC) Latest News

Dec 21, 2025

Will Ensysce Biosciences Inc. stock maintain growth storyWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда

Dec 21, 2025

Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN

Dec 21, 2025

What sentiment indicators say about Ensysce Biosciences Inc. stockTrade Entry Summary & Fast Momentum Entry Tips - Улправда

Dec 21, 2025

Why Ensysce Biosciences Inc. stock is considered a top pick2025 Trading Volume Trends & Weekly Stock Breakout Alerts - Улправда

Dec 21, 2025

Dec 20, 2025

How buybacks impact Ensysce Biosciences Inc. stock valueEarnings Performance Report & Community Shared Stock Ideas - Улправда

Dec 20, 2025

Can Ensysce Biosciences Inc. stock maintain operating margins2025 AllTime Highs & Verified Stock Trade Ideas - Улправда

Dec 20, 2025

How Ensysce Biosciences Inc. stock reacts to Fed rate cutsWeekly Trade Report & Real-Time Volume Trigger Notifications - Улправда

Dec 20, 2025

Dec 19, 2025

Resistance Check: Can Ensysce Biosciences Inc. stock maintain operating marginsMarket Performance Report & High Return Trade Guides - Улправда

Dec 19, 2025

Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - Улправда

Dec 19, 2025

Dec 15, 2025

Ensysce Biosciences Earnings Notes - Trefis

Dec 15, 2025

Dec 13, 2025

EBIT per share of Ensysce Biosciences Inc. – OTC:ENSCW - TradingView — Track All Markets

Dec 13, 2025

Dec 11, 2025

ENSC enrolls first patient in critical phase 3 trial - MSN

Dec 11, 2025

Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614 - MSN

Dec 11, 2025

Dec 10, 2025

Ensysce Biosciences enrolls first patient in phase 3 pain drug trial - Investing.com Australia

Dec 10, 2025

Dec 09, 2025

Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade

Dec 09, 2025

Is Ensysce Biosciences a Hidden Gem? - timothysykes.com

Dec 09, 2025

Ensysce Biosciences enrolls first patient in phase 3 pain drug trial By Investing.com - Investing.com South Africa

Dec 09, 2025

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Corsicana Daily Sun

Dec 09, 2025

Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid - Stock Titan

Dec 09, 2025

Dec 04, 2025

How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser

Dec 04, 2025

Dec 03, 2025

Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser

Dec 03, 2025

Dec 02, 2025

Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan

Dec 02, 2025

Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser

Dec 02, 2025

Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser

Dec 02, 2025

Dec 01, 2025

Ensysce Biosciences (ENSC) Stock Analysis Report | Financials & Insights - Benzinga

Dec 01, 2025

Nov 28, 2025

Earnings Beat: Why Ensysce Biosciences Inc. stock is seen as undervalued2025 Volatility Report & Fast Gaining Stock Reports - moha.gov.vn

Nov 28, 2025

Is Ensysce Biosciences, Inc. overvalued or undervalued? - Markets Mojo

Nov 28, 2025

Nov 24, 2025